Abstract: A transmission assembly comprising: a transmission housing, a multi-stage transmission that can be drivingly connected to an internal combustion engine, a reduction gearing that can be drivingly connected to an electric motor, a differential gearing with a differential input gear that meshes with a transmission output gear and a reduction gearing output gear, wherein the transmission output gear is arranged axially outside a space formed between a first gear plane and a second gear plane of the multi-stage transmission. The disclosure also relates to a hybrid assembly with such a transmission assembly.

Abstract: The disclosure provides compositions containing pure aticaprant, solvates of aticaprant, and methods of treating major depressive disorder using aticaprant.

Abstract: A database system includes data ingest sub-system, a data ingest network interface, and a data store and analytics (S&A) sub-system. The data ingest network interface provides data of a first data set per a first data ingest option to a first set of the sets of data_in computing clusters, which temporarily stores the data of the first data set. The data ingest network interface further provides data of a second data set per a second data ingest option to a second set of the sets of data_in computing clusters, which temporarily stores the data of the second data set. A first set of the sets of data_S&A computing clusters is operable to long-term and resiliently store the data of the first data set. The first set of data_S&A computing clusters executes a first set of operational instructions on the data of the first data set to produce a set of first partial results.

Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Abstract: A Munitions Payload Delivery System (MPDS) is provided. One embodiment of the MPDS comprises a multi-rotor drone configured to carry a munition in the form of a HEDP linear-shaped charge or Armor Piercing munition or other-shaped munition. The drone, in one embodiment, includes a camera that provides a remote operator with a real-time video feed so the operator can pilot the drone to a specific target on a battlefield. Once a target is selected, the operator ignites the munition by flying the drone into the target, landing the drone on the target, or activating a radio fire button. In one embodiment, each of these mechanisms closes a switch on board the drone connecting a voltage to a blasting cap inside the payload.

Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.

Abstract: A database system is operable to communicate first system metadata to a plurality of nodes in a first temporal period, where each node of the plurality of nodes updates corresponding system configuration data as the first system metadata. At least one database function is performed in the first temporal period via the plurality of nodes operating in conjunction with the first system metadata. Updated system metadata is determined based on a first metadata change applied the first system metadata. The first metadata change is communicated to the plurality of nodes in a second temporal period, where each node further updates the corresponding system configuration data as the updated system metadata based on applying the first metadata change to the first system metadata. The at least one database function is performed in the second temporal period via the plurality of nodes operating in conjunction with the updated system metadata.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Abstract: A Munitions Payload Delivery System (MPDS) is provided. One embodiment of the MPDS comprises a multi-rotor drone configured to carry a munition in the form of a HEDP linear-shaped charge or Armor Piercing munition or other-shaped munition. The drone, in one embodiment, includes a camera that provides a remote operator with a real-time video feed so the operator can pilot the drone to a specific target on a battlefield. Once a target is selected, the operator ignites the munition by flying the drone into the target, landing the drone on the target, or activating a radio fire button. In one embodiment, each of these mechanisms closes a switch on board the drone connecting a voltage to a blasting cap inside the payload.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Abstract: A drive assembly comprises at least an electric drive having a drive shaft, and a transmission having at least one input shaft, wherein a drive power of the electric drive can be transmitted to the input shaft via the drive shaft, and can be transmitted from the input shaft into the transmission. The drive shaft and the input shaft are coaxial to one another and are interconnected by way of a toothing that is form-fitting at least in a circumferential direction. The drive shaft and the input shaft are at least frictionally connected at least in relation to an axial direction at least via a press fit formed in each case between an inner circumferential surface and an outer circumferential surface which are parallel to an axis of rotation, or the drive shaft and the input shaft together form a form-fitting connection via a connecting element.

Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.

Abstract: A high-voltage component includes a housing and a high-voltage connection arranged therein. The housing includes a cover element, which closes an opening of the housing. The high-voltage connection is accessible from the outside exclusively via the opening. The cover element is releasably connected to the housing via a plurality of connecting elements. A cable extends, from a non-detachable first connection arranged on the housing, outside the housing at least partially over the cover element to a second connection arranged on the housing in such a way that at least one first connecting element is covered by the cable and is thus not accessible from the outside.

Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.

Abstract: A cable for a hearing device, comprising a plurality of conductors, comprising conductors arranged in twisted pairs (TP1 to TP4) wound around a plastically deformable core wire (FW).